Rundu Pharma: Obtained the drug registration certificate for Isosorbide Mononitrate Tablets
On the evening of August 25th, Rundu Pharma announced that the company recently received the "Drug Registration Certificate" for Isosorbide Mononitrate Tablets issued by the National Medical Products Administration. This product is suitable for the long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; and in combination with digoxin and/or diuretics for the treatment of chronic congestive heart failure
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments